Oncolytics Biotech Inc. (ONCY)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Oncolytics Could Re-Rate As Pelareorep Focuses On Registrational Paths
Oncolytics is narrowing Pelareorep development toward anal cancer and metastatic colorectal cancer, making its bull case more concrete. Pelareorep may turn “cold” tumors “hot,” potentially improving chemotherapy and checkpoint inhibitor responses across GI cancers. CRC data showed an unusually high 33% ORR versus 6%-11% historical SoC. This is why it received the FDA's Fast Track designation.
Oncolytics Biotech Inc. (ONCY) Shareholder/Analyst Call Prepared Remarks Transcript
Oncolytics Biotech Inc. (ONCY) Shareholder/Analyst Call Prepared Remarks Transcript
Oncolytics Biotech (ONCY) Loses 8.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Oncolytics Biotech (ONCY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Oncolytics Biotech Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| SE Sima Elimelech Activest Wealth Management | 5,000 | $4,950 | $4,520 | -$430 | -8.69% |
| PIL PFG Investments LLC PFG Investments LLC | 52,900 | $50,158.31 | $46,023 | -$4,135.31 | -8.24% |
 Kevin Bresler TD Waterhouse Canada Inc. | 662 | $618.42 | $579.38 | -$39.04 | -6.31% |
 KURT TRAULSEN EVOLUTION WEALTH MANAGEMENT INC. | 105 | $89 | $91.93 | $2.93 | 3.29% |
| DMM Dianne Marie Morin SEEDS INVESTOR LLC | 258,306 | $262,544.07 | $224,157.95 | -$38,386.12 | -14.62% |
Oncolytics Biotech Inc. (ONCY) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Oncolytics Biotech Inc. ever had a stock split?
Oncolytics Biotech Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jared Kelly CEO | NASDAQ (CM) Exchange | 68237V103 CUSIP |
| US Country | 29 Employees | - Last Dividend | 25 May 2018 Last Split | - IPO Date |
Overview
Oncolytics Biotech Inc. operates within the cutting-edge field of biopharmaceuticals, dedicating its resources and expertise to the discovery and development of novel pharmaceutical treatments specifically targeting cancer. As a clinical-stage company, its primary focus revolves around advancing the research, development, and eventual commercialization of cancer therapeutics. The collaborative efforts with leading pharmaceutical entities such as Merck KGaA, Pfizer Inc., and Roche Holding AG further exemplify Oncolytics' commitment to leveraging partnerships to augment the development process of its key product candidates. Founded in 1998, Oncolytics has established its headquarters in Calgary, Canada, positioning itself at the forefront of cancer research innovation.
Products and Services
Pelareorep: Positioned as the cornerstone of Oncolytics Biotech's developmental portfolio, pelareorep is an intravenously delivered immunotherapeutic agent. Currently, it is undergoing a phase 3 clinical trial, demonstrating its potential efficacy against hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer. This product embodies the company's concerted effort to harness the power of the immune system in combating cancer, showcasing a novel approach to oncological treatment. Furthermore, pelareorep's application is being explored in the treatment of advanced/metastatic pancreatic ductal adenocarcinoma, signifying its versatility and the broad scope of its potential therapeutic impact.
